

Special Issue

Health Technology Assessment of Vaccination: Strategies, Public Health and Values

Message from the Guest Editors

Health Technology Assessment (HTA) has an increasing role worldwide in the accessibility and use of vaccines. This Special Issue aims to bring together the views and interests of different stakeholders to enhance mutual understanding. The topics to be addressed include time-to-population access vaccine studies, cost-effectiveness analyses, real-world monitoring of vaccine performances, and guidelines for adequate vaccine HTA evaluations. Specific aims include a better understanding of vaccine hesitancy, long periods of population access, roles of cost-effectiveness and budgets, views of patient groups, and the advantages of vaccines. Original research articles and reviews, within the journal's scope, are welcome for submission, focusing on themes such as the value of vaccines, the time it takes for innovative vaccines to reach patients, cost-effectiveness assessments, real-world data analyses on vaccines' properties, and overcoming vaccine hesitancy to increase coverage. We look forward to receiving valuable contributions.

Guest Editors

Prof. Dr. Maarten J. Postma
Dr. Jurjen Van der Schans
Prof. Dr. Cornelis Boersma

Deadline for manuscript submissions

closed (31 December 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/208027

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).